RIVOPAM TABLET 0.5MG

Страна: Малайзія

мова: англійська

Джерело: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Активний інгредієнт:

CLONAZEPAM

Доступна з:

DUOPHARMA (M) SDN. BHD.

ІПН (Міжнародна Ім'я):

CLONAZEPAM

Одиниць в упаковці:

500 Tablets

Виробник:

DUOPHARMA (M) SDN. BHD.

інформаційний буклет

_Consumer Medication Information Leaflet (RIMUP) _
1
RIVOPAM TABLET
Clonazepam (0.5mg/2mg)
WHAT IS IN THE LEAFLET?
1.
What
RIVOPAM
is
used
for
2.
How RIVOPAM works
3.
Before you use RIVOPAM
4.
How to use RIVOPAM
5.
While you are using it
6.
Side effects
7.
Storage
and
Disposal
of
RIVOPAM
8.
Product Description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of Revision
WHAT RIVOPAM IS USED FOR
Rivopam
is
used
to
treat
epilepsy
in
infants,
children
and
adults.
It
lowers
the
number of fits (seizures) that
you have.
Ask your doctor if you have
any
questions
about
why
Rivopam
Tablet
has
been
prescribed for you.
HOW RIVOPAM WORKS
Rivopam contains a medicine
called
clonazepam.
This
belongs
to
a
group
of
medicines
called
‘benzodiazepines’.
BEFORE YOU USE RIVOPAM
-
_When you must not use it _
Do not take Rivopam if you are
allergic to:

medicines
containing
clonazepam
or
other
benzodiazepines

any
of
the
ingredients
listed
at
the
end
of
this
leaflet.

Some of the symptoms of
an
allergic
reaction
may
include skin rash, itching
or hives; swelling of the
face, lips or tongue, which
may
cause
difficulty
in
swallowing
or
breathing;
wheezing or shortness of
breath.
Do not take Rivopam if you
have:

respiratory
depression
(decreased
rate
of
breathing)

lung disease

an addiction to alcohol.
If it has expired or is damaged,
return it to your pharmacist for
disposal.
If you are not sure whether you
should
start
taking
this
medicine, talk to your doctor.
-
_Before you start to use it _
_ _

Tell your doctor if you are
allergic
to
any
other
medicines, foods, dyes or
preservatives.

Tell your doctor if you are
pregnant
or
plan
to
become pregnant.

It
is
not
known
whether
Rivopam
is
safe
to
use
during pregnancy.

Therefore,
if
there
is
a
need
to
take
Rivopam
during
pregnancy,
your
doctor
will
discuss
the
risks and benefits with you.

Tell your doctor if you are
breastfeeding
or
plan
to
breastfeed.

Rivopam
is
not
recommended
for
use
during breastfeeding as it
passes into the breast mil

Характеристики продукта

Page 1 of 2
[REVISION DATE: 16.08.2019]
[DUOPHARMA (M) SDN BHD]
RIVOPAM TABLET
DESCRIPTION:
RIVOPAM TABLET 0.5 MG
: A white 7 mm round tablet with marking 'd' and a 'flower'.
RIVOPAM TABLET 2MG : A white 7 mm round tablet with marking 'DUO 861'
on the scored side and 'd' on another side.
COMPOSITION:
RIVOPAM TABLET 0.5 MG
: Each tablet contains Clonazepam 0.5 mg.
RIVOPAM TABLET 2 MG
: Each tablet contains Clonazepam 2 mg.
PHARMACODYNAMICS:
The active substance of clonazepam is a benzodiazepine derivative,
closely related to nitrazepam and diazepam, exhibiting marked
anticonvulsant properties in animals. Clonazepam
prevents generalisation of convulsive activity. In the majority of
cases, clonazepam improves both focal seizures and primarily
generalised attacks.
PHARMACOKINETICS:
Clonazepam is nearly completely absorbed after oral administration
with peak serum levels being reached between 2 and 3 hours. The volume
of distribution is 2-3 litres/kg.
Clonazepam is metabolised by the liver and pathways include
hydroxylation and reduction of the nitro group.
INDICATION:
The majority of clinical forms of epileptic disease in infants and
children, especially typical or atypical petit mal epilepsies,
tonic-clonic seizures generalised from the onset or
secondarily, status epileptics in all its clinical forms. Clonazepam
has also demonstrated efficacy in both major and minor seizures in
adults including grand mal, petit mal, (classical
and atypical forms) and in psychomotor, myoclonic, focal and tonic and
atonic seizures.
RECOMMENDED DOSAGE:
ORAL TREATMENT: Dosage of clonazepam is essentially individual and
depends in the first instance on the age of the patient. It will be
determined in each patient according to clinical
response and tolerance. In order to minimise initial adverse reaction
it is essential to commence with low doses and increase the daily dose
progressively until a maintenance dose
suited to the individual patient has been reached. Some degree of
tolerance may be observed to both the adverse and therapeutic